1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Drug Discovery Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising R&D Expenditure in the Pharmaceutical & Biopharmaceutical industry
5.1.1.2. Increasing Need to Manage Large Data Generated During Preclinical Studies
5.1.1.3. Favorable Government Support For the Development of Drug Discovery Platforms
5.1.2. Restraints
5.1.2.1. Requirement of Extensive Capital for Drug Discovery and Development
5.1.3. Opportunities
5.1.3.1. Technological Advancements and Innovations in Drug Discovery
5.1.3.2. Use of AI Cloud to Create a Streamlined and Automated Approach in Drug Discovery
5.1.4. Challenges
5.1.4.1. Stringent Norms for the Animal Usage in Drug Discovery
5.2. Market Segmentation Analysis
5.2.1. Drug Type: Growing need for small molecule drugs with branded and generic products
5.2.2. Technology: Growing utilization of bioanalytical instruments and high throughput screening for initial drug discovery phases
5.2.3. Therapeutic Area: Increasing need of drug discovery for the development of oncology drugs
5.2.4. End User: Growing drug discovery use across pharmaceutical and biotechnology companies for developing new and improved drugs
5.3. Market Trend Analysis
5.3.1. Preference for advanced and innovative drug discovery technologies in the Americas
5.3.2. Proliferating number of clinical trials and availability of tax-incentives for drug development across the Asia-Pacific
5.3.3. Supportive government funding and initiatives for drug discovery and development in the EMEA region
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
6. Drug Discovery Market, by Drug Type
6.1. Introduction
6.2. Biologic Drugs
6.3. Small Molecule Drugs
7. Drug Discovery Market, by Technology
7.1. Introduction
7.2. Bioanalytical Instruments
7.3. Biochips
7.4. Bioinformatics
7.5. Combinatorial Chemistry
7.6. High Throughput Screening
7.7. Nanotechnology
7.8. Pharmacogenomics
8. Drug Discovery Market, by Therapeutic Area
8.1. Introduction
8.2. Cardiovascular Disease
8.3. Digestive System Diseases
8.4. Infectious & Immune system Diseases
8.5. Neurology
8.6. Oncology
9. Drug Discovery Market, by End User
9.1. Introduction
9.2. Academics & Research Institutes
9.3. Contract Research Organizations
9.4. Pharmaceutical Companies
10. Americas Drug Discovery Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Drug Discovery Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Drug Discovery Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
13.3.1. Merger & Acquisition
13.3.1.1. Recursion Plans USD 87.5m Acquisitions To Shore Up AI Drug Discovery
13.3.1.2. Eurofins Discovery Acquires CALIXAR, Expanding Integrated Drug Discovery Capabilities and Expertise
13.3.2. Agreement, Collaboration, & Partnership
13.3.2.1. Evommune and Accutar Biotechnology Announce AI Drug Discovery Collaboration
13.3.2.2. IGC Pharma signs agreement to adopt AI solutions into drug discovery
13.3.2.3. University of Tsukuba and Astellas Confirm a Strategic Partnership
13.3.2.4. Sosei and PharmEnable collaborate on another neurological drug
13.3.2.5. Novo Nordisk and Evotec launch translational drug discovery accelerator
13.3.3. New Product Launch & Enhancement
13.3.3.1. Revvity Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development
13.3.3.2. Google Cloud Launches AI-powered Solutions to Safely Accelerate Drug Discovery and Precision Medicine
13.3.3.3. PerkinElmer Unveils Multimode Plate Reader To Expedite Drug Discovery
13.3.4. Investment & Funding
13.3.4.1. Mestastop Raises USD 500k To Further Its Cancer Drug Discovery
13.3.4.2. Genesis Raises USD 200 Million For AI Drug Discovery Research
13.3.4.3. BenchSci Raises USD 95 Million Series D Funding to Enable Drug Discovery Innovation at Scale With its Groundbreaking AI Platform ASCEND
13.3.5. Award, Recognition, & Expansion
13.3.5.1. LabGenius Secures Government Innovation Grant to Expand ML-driven Drug Discovery Platform, EVA
13.3.5.2. Incyte Announces FDA Approval Of Pemazyre (Pemigatinib) As Targeted Treatment For Myeloid/Lymphoid Neoplasms (MLNs) With FGFR1 Rearrangement
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Abbott Laboratories
14.1.2. Agilent Technologies, Inc.
14.1.3. Alacrita Holdings Limited
14.1.4. Astex Pharmaceuticals by Otsuka Pharmaceutical Co., Ltd.
14.1.5. Astrazeneca PLC
14.1.6. Atomwise, Inc.
14.1.7. BenevolentAI
14.1.8. Bio-Rad Laboratories, Inc.
14.1.9. BioSymetrics Inc.
14.1.10. Charles River Laboratories International, Inc.
14.1.11. Chembridge Corporation
14.1.12. Cloud Pharmaceuticals, Inc.
14.1.13. Dalriada Drug Discovery
14.1.14. Deciphera Pharmaceuticals, Inc.
14.1.15. Evotec SE
14.1.16. F. Hoffmann-La Roche Ltd.
14.1.17. GENFIT SA
14.1.18. Incyte Corporation
14.1.19. International Business Machines Corporation
14.1.20. Intra-Cellular Therapies Inc.
14.1.21. Merck KGaA
14.1.22. Microsoft Corporation
14.1.23. NVIDIA Corporation
14.1.24. PerkinElmer, Inc.
14.1.25. Pharmacelera SL
14.1.26. Piramal Group
14.1.27. Recursion Pharmaceuticals, Inc.
14.1.28. Schrödinger, Inc.
14.1.29. Shimadzu Corporation
14.1.30. Thermo Fisher Scientific Inc.
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
